PPCB underwent a dramatic share consolidation reducing outstanding shares from 688 million to 13 million while maintaining minimal cash reserves and increasing liabilities substantially.
The massive reduction in share count (approximately 98.1%) indicates a significant reverse stock split, likely implemented to address compliance issues or improve share price perception. The company's financial position remains precarious with only $4K in cash while liabilities grew to $5.7M, suggesting ongoing funding challenges for this biotech operation.
The company's balance sheet shows a mixed picture with cash increasing modestly from $2K to $4K, though this remains critically low for operations. Total liabilities expanded meaningfully to $5.7M, while current liabilities also grew substantially, indicating mounting operational pressures. Operating cash flow improved notably but remained deeply negative at -$405K, while capital expenditures declined significantly, suggesting constrained investment capacity.
Cash position surged 80.4% — strong cash generation or capital raise providing significant financial cushion.
Capex reduced 70.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow surged 56.7% — exceptional cash generation, highest quality earnings signal.
Liabilities grew 48.7% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 47.1% — significant near-term obligations; verify ability to meet short-term debt.
Debt increased 34.7% — substantial leverage increase; assess whether deployed for growth or covering losses.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →